Katalog Plus
Bibliothek der Frankfurt UAS
Bald neuer Katalog: sichern Sie sich schon vorab Ihre persönlichen Merklisten im Nutzerkonto: Anleitung.
Dieses Ergebnis aus BASE kann Gästen nicht angezeigt werden.  Login für vollen Zugriff.

Changes in liver steatosis evaluated by transient elastography with the controlled attenuation parameter in HIV‐infected patients

Title: Changes in liver steatosis evaluated by transient elastography with the controlled attenuation parameter in HIV‐infected patients
Authors: Macías, J; Real, LM; Rivero‐Juárez, A; Merchante, N; Camacho, A; Neukam, K; Rivero, A; Mancebo, M; Pineda, JA
Contributors: Consejería de Salud de la Junta de Andalucía; Ministerio de Sanidad, Política Social e Igualdad; Programa de Intensificación de la Actividad de Investigación del Servicio Nacional de Salud español; Fundación Progreso y Salud of the Consejería de Salud de la Junta de Andalucía; Servicio Andaluz de Salud de la Junta de Andalucía; Plan Nacional R + D + I; ISCIII-Subdirección General de Evaluación y el Fondo Europeo de Desarrollo Regional, (FEDER)
Source: HIV Medicine ; volume 17, issue 10, page 766-773 ; ISSN 1464-2662 1468-1293
Publisher Information: Wiley
Publication Year: 2016
Collection: Wiley Online Library (Open Access Articles via Crossref)
Description: Objectives There are scant data on the progression of hepatic steatosis ( HS ) in HIV infection. We therefore evaluated changes in HS over time in HIV ‐infected patients using the controlled attenuation parameter ( CAP ). Methods A prospective cohort of 326 HIV ‐infected patients was included in this study. All patients underwent a CAP measurement. Changes in steatosis were evaluated by calculating the median (Q1–Q3) difference between baseline and 12‐month CAP values. Results The median (Q1–Q3) CAP was 221 (196–252) dB /m at baseline and 224 (198–257) dB /m at the 12‐month visit ( P = 0.617). Significant steatosis, that is, CAP ≥ 238 dB /m, was observed in 76 individuals (37%) at baseline and in 80 (39%) at the 12‐month visit ( P = 0.683). The following variables were associated with Δ CAP : plasma HIV RNA [< 50 vs . ≥ 50 HIV ‐1 RNA copies/ mL : median (Q1–Q3) Δ CAP , 4 (−21, 27) vs . −21 (−49, 4) dB /m, respectively; P = 0.024]; body mass index ( BMI ) [no increase vs . increase: −13 (−40, 4) vs . 14 (−6, 32) dB /m, respectively; P < 0.001]; triglycerides [no increase vs . increase: −1 (−30, 22) vs . 15 (−3, 40) dB /m, respectively; P = 0.001]; fasting plasma glucose [not impaired vs . impaired: −4 (−31, 16) vs . 30 (15, 49) dB/m, respectively; P < 0.001]; and raltegravir [no vs . yes: 5 (−20, 29) vs . −11 (−37.5, 15) dB/m, respectively; P = 0.018]. The only factor independently associated with Δ CAP was BMI [B (standard error): 9.03 (1.9); P < 0.001]. Conclusions Increases in CAP values over a period of 12 months in HIV ‐infected patients were strongly associated with elevations in BMI . Other metabolic factors and antiretroviral drugs were not predictors of CAP changes independent of BMI .
Document Type: article in journal/newspaper
Language: English
DOI: 10.1111/hiv.12384
Availability: http://dx.doi.org/10.1111/hiv.12384; https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Fhiv.12384; https://onlinelibrary.wiley.com/doi/pdf/10.1111/hiv.12384
Rights: http://onlinelibrary.wiley.com/termsAndConditions#vor
Accession Number: edsbas.F0F2F58E
Database: BASE